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Abstract: Members of the tripartite motif family of E3 ubiquitin ligases are characterized by the
presence of a conserved N-terminal module composed of a RING domain followed by one or
two B-box domains, a coiled-coil and a variable C-terminal region. The RING and B-box are both
Zn-binding domains but, while the RING is found in a large number of proteins, the B-box is exclusive
to the tripartite motif (TRIM) family members in metazoans. Whereas the RING has been extensively
characterized and shown to possess intrinsic E3 ligase catalytic activity, much less is known about
the role of the B-box domains. In this study, we adopted an in vitro approach using recombinant
point- and deletion-mutants to characterize the contribution of the TRIM32 Zn-binding domains to
the activity of this E3 ligase that is altered in a genetic form of muscular dystrophy. We found that the
RING domain is crucial for E3 ligase activity and E2 specificity, whereas a complete B-box domain
is involved in chain assembly rate modulation. Further, in vitro, the RING domain is necessary to
modulate TRIM32 oligomerization, whereas, in cells, both the RING and B-box cooperate to specify
TRIM32 subcellular localization, which if altered may impact the pathogenesis of diseases.
Keywords: TRIM family; E3 ubiquitin ligases; RING domain; B-box domain; Limb–Girdle Muscular
Dystrophy type 2H
1. Introduction
Ubiquitination is a versatile form of post-translational modification that regulates a large
number of processes inside the cell through the regulation of protein turnover and activity. The
ubiquitination reaction is a three-step process beginning with the ATP-dependent activation of
ubiquitin, a 76-amino-acid peptide, by the E1 activating enzyme. In the following step of the cascade,
ubiquitin is transferred to the E2-conjugating enzyme, which then cooperates with an E3 ubiquitin
ligase to transfer ubiquitin to the final target substrate [1]. Thus, the E3 ubiquitin ligase is able to
provide substrate specificity to the ubiquitination cascade. In humans, the vast majority of E3 ligases
possess a really interesting new gene (RING) domain, which confers catalytic activity (reviewed in [2]).
Among the RING-type E3 ligases, the tripartite motif (TRIM) family represents one of the largest
groups with over 70 members in humans. This class of E3 ligases is characterized by the presence of
a well-conserved N-terminal motif comprising the previously mentioned RING domain, one or two
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B-box domains and a coiled-coil region [3]. The C-terminal domain is highly variable among different
members of the family and is supposed to provide substrate specificity [4–6].
The RING domain of several TRIM proteins was shown to fold around two Zn2+ ions coordinated
by conserved Cysteine and Histidine residues, while the formation of a 4-helix bundle by residues N-
and C-terminal to the Zn-binding core allows for the RING dimerization necessary for ubiquitination
activity [7,8]. Mechanistically, RING-type ubiquitin ligases were shown to contact the ubiquitin-loaded
E2, promoting a conformational change that allows for the direct transfer of ubiquitin to the substrates
without the formation of an intermediate bond between ubiquitin and the E3 ligase [9–11]. In this
context, the dimerization of the RING domains provides the proper interaction surface to contact
both the E2 and ubiquitin, ultimately allowing the discharge of ubiquitin from the loaded E2 to the
substrate. In TRIM proteins, the B-box domain, C-terminal to the RING, assumes a fold similar to the
latter through the coordination of Zn ions by conserved Cysteine, Histidine and Aspartate residues.
The B-box domain can be present in two flavors, type 1 and 2, that have been well conserved during
evolution as part of the tripartite motif, invariably located between the RING and the coiled-coil region
in a unique (type 2) or tandem arranged (type 1–type 2) manner [5,12–14]. Whether this domain elicits
or contributes to the E3 catalytic activity given its similarity with the RING domain is still controversial.
Finally, in all the TRIM proteins studied, a coiled-coil region invariantly follows the B-box domain(s)
and assumes a typical α-helical structure. The interaction of the coiled-coil domains of two TRIM
proteins allows for the formation of anti-parallel dimers, resulting in N-terminal domains at opposed
ends of the rod-like structures [15–17]. Therefore, the higher order self-association of dimers may be
required to allow for the RING dimerization necessary for catalytic activity, as has been shown in the
case of TRIM5α [18–20].
The TRIM32 tripartite motif is composed of a RING domain followed by a single type 2 B-box
and a coiled-coil domain. The C-terminus in TRIM32 is composed of six NHL repeats (named after
proteins Ncl-1, HT2A and Lin-41 containing this domain) shown to be involved in the recognition of
various substrates [21]. Importantly, a cluster of mutations in the C-terminal domain or the complete
deletion of the gene were shown to be associated with the neuromuscular disease Limb–Girdle
Muscular Dystrophy type 2H, a recessive form of late-onset muscular dystrophy mainly affecting the
proximal muscles of limbs [22–24]. In the disease context, TRIM32 may affect muscle physiology at
many different levels, from atrophy to the regeneration of damaged fibers [21,25–28]. Interestingly,
a P130S mutation in the B-box domain is associated with a non-muscular phenotype, Bardet–Biedl
Syndrome (BBS), although the pathogenetic mechanism is yet to be elucidated [29]. Furthermore,
like many other members of the TRIM family, TRIM32 was also shown to play a role in cancer since
various oncogenes (e.g., MYCN) or tumor suppressors (e.g., p53) are among its substrates (reviewed
in [21]). Given the multiple roles TRIM32 can have in both physiological and pathological conditions,
understanding in detail the mechanism of action of this enzyme is important for the correct design of
therapeutic strategies.
Here, we performed a biochemical analysis aimed at investigating TRIM32 cooperation with
various E2-conjugating enzymes and the role of the Zn-binding domains in the regulation of its activity.
2. Materials and Methods
2.1. Constructs and Mutagenesis
The mammalian expression plasmids encoding the human TRIM32 sequence in pcDNA3X(+)-
Myc-GFP and pcDNA3X(+)-HA were described previously [3]. The sequence encoding human
TRIM32 was inserted in the bacterial expression plasmid, pETM11, using the restriction-free cloning
method [30]. Briefly, the TRIM32 sequence was amplified using primers N1 and C5 (the full list of
primers used in this study is available in Table 1), containing over-hanging tails complementary to
the destination vector, and pcDNA3X(+)-Myc-GFP-TRIM32 as a template. The PCR product was
subsequently purified and used as a primer pair for the second PCR reaction, which includes the
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destination vector as a template for a linear amplification reaction around the plasmid resulting
in insertion of the sequence of interest in the vector. A primer (N2) annealing internally in the
TRIM32 sequence was used in combination with the previously mentioned C5 primer to generate the
mutant lacking the N-terminal 88 amino acids (TRIM32 ∆RING). Point mutations and the internal
deletion of the B-box (∆B-box, lacking residues 99–134) were generated by site-directed mutagenesis
using primers listed in Table 1 and the QuikChange mutagenesis kit (Stratagene). The plasmid
encoding His6-MBP-tagged UbE2V2 in pLou3 vector was a kind gift from Prof. Ronald T. Hay
(University of Dundee).
Table 1. List of primers used in this study. For mutagenizing primers, bases bordering the deletion
(∆B-box) or corresponding to the mutations (C100A/C103A) are in red.
TRIM32
Forward (N1) 5′-gagaatctttattttcagggcgccatggctgcagcagcagcttctcac-3′
Reverse (C5) 5′-caagcttgtcgacggagctcgaattcctatggggtggaatatcttctcagatggta-3′
TRIM32 ∆RING (∆1–88)
Forward (N2) 5′-gagaatctttattttcagggcgccgctgggctcagcgaggctgtggggc-3′
Reverse (C5) 5′-caagcttgtcgacggagctcgaattcctatggggtggaatatcttctcagatggta-3′
TRIM32 ∆B-box (∆99–134)
Forward 5’-agctgcttctttgacagggagtggcagcagccccacagcctcgctgag-3’
Reverse 5’-ctcagcgaggctgtggggctgctgccactccctgtcaaagaagcagct-3’
TRIM32 C100A/C103A
Forward 5’-cagacgccgcccagcggaccgagccatgagcagcccc-3’
Reverse 5’-ggggctgctcatggctcggtccgctgggcggcgtctg-3’
2.2. Protein Expression and Purification
Plasmids (pETM11) encoding His6-tagged human TRIM32 (wild-type or mutated forms) were
transformed into BL21(DE3) RIPL Escherichia coli cells. Cultures were grown at 37 ◦C in Terrific
Broth until OD600 reached 0.6–0.8 and the expression of recombinant proteins was then induced
by addition of 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and 100 µM ZnCl2 followed by
incubation at 16 ◦C overnight. Bacteria were lysed in lysis buffer (50 mM TRIS, pH 8; 0.5 M NaCl;
10 mM imidazole; 5 mM β-Mercaptoethanol and protease inhibitor cocktail (Roche)). Bacteria lysis
was achieved by addition of lysozyme (250 µg/mL) and sarkosyl (0.3%) followed by sonication. Triton
X-100 was then added to a final concentration of 0.5% before centrifugation to remove the insoluble
fraction. Recombinant proteins were purified by incubation with Ni-NTA resin (Qiagen; Hilden,
Germany) followed by washes with lysis buffer containing 50 mM imidazole. The resin was eluted
in elution buffer (20 mM TRIS pH 8; 250 mM NaCl; 10% glycerol; 200 mM imidazole and 5 mM
β-Mercaptoethanol) and the recombinant proteins were dialyzed overnight against 20 mM TRIS pH 8;
0.5 M NaCl; 10% glycerol and 5 mM β-Mercaptoethanol.
2.3. In Vitro Ubiquitination
Recombinant proteins used for in vitro ubiquitination assays were purchased from Boston
Biochem (Cambridge, MA, USA) (UBE1 activating enzyme, UbE2D1, UbE2N), Sigma (St. Louis, MO,
USA) (ubiquitin) or UBPBio (Aurora, CO, USA) (E2 screening kit). Recombinant His6-MBP-tagged
UbE2V2 was purified as described in [10]. Ubiquitination reactions were carried out at 37 ◦C and
contained 50 nM E1, 1 µM E2, 50 µM ubiquitin in reaction buffer (50 mM TRIS pH 7.2; 150 mM NaCl;
0.1% NP-40; 0.1 mM Tris (2-carboxyethyl) phosphine (TCEP); 3 mM ATP and 5 mM MgCl2). The
quantity of E3 added varied in different assays and in assays where different TRIM32 mutants were
employed, comparable amounts of each recombinant protein were used. The E2 screening kit was
used according to the manufacturer’s instructions. Reactions were stopped by addition of Laemmli
buffer containing 100 mM Dithiothreitol (DTT) final concentration.
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2.4. Cell Culture and Transfection
The C2C12 murine myoblast cell line (kind gift from Prof. Paola D’Andrea, University of
Trieste) was grown in high glucose Dulbecco’s Modified Eagle Medium (DMEM)medium without
sodium pyruvate supplemented with 20% Fetal Bovine Serum (FBS), 4 mM L-glutamine, 100 U/mL
penicillin and 100 µg/mL streptomycin, and maintained at 37 ◦C in 5% CO2. C2C12 cells were
seeded on coverslips and transfected with HA- or Myc-GFP-tagged constructs using Lipofectamine
3000 according to the manufacturer’s instructions the day after seeding.
2.5. Immunofluorescence
Twenty-four to forty-eight hours post-transfection, cells were fixed in 4% Paraformaldehyde
(PFA) in Phosphate Buffer Saline (PBS) for 10 min at room temperature. For immunofluorescence
analysis, cells were permeabilized with 0.1% Triton X-100 in PBS and blocked with 5% Bovine Serum
Albumin (BSA) in 0.1% Triton X-100 in PBS. Cells were stained with anti-HA antibody and FITC- or
Cy3-conjugated secondary antibodies. Coverslips were mounted with Vectashield mounting medium
with 4′,6-diamidino-2-phenylindole (DAPI) and analyzed by epifluorescent microscopy.
2.6. Antibodies and Immunoblot Analysis
Samples from the in vitro ubiquitination reactions were boiled and resolved by SDS-PAGE on
4–15% gradient gels (Bio-Rad). For native PAGE, proteins were prepared in Laemmli buffer lacking SDS
and DTT and resolved without prior boiling on a 7.5% poly-acrylamide gel without SDS. Following
transfer to PVDF membranes, target proteins were detected with anti-ubiquitin (UBPBio, clone P4D1)
and anti-TRIM32 (Abcam, Cambridge, UK; ab96612), and relevant HRP-tagged secondary antibodies.
Signal was detected using ECL substrate (Millipore, Burlington, MA, USA) and autoradiography films
(GE Healthcare, Chicago, IL, USA). In some cases, membranes were stripped with mild stripping buffer
(200 mM glycine; 0.1% SDS; 1% Tween 20; pH 2.2) prior to re-probing with a different primary antibody.
2.7. Quantification of In Vitro Ubiquitination Activity
Following the in vitro ubiquitination reaction as described in Section 2.3, proteins were resolved
on 4–15% gradient gels (Bio-Rad; Hercules, CA, USA) followed by transfer on PVDF membranes and
blotting with anti-ubiquitin antibody. For the time course in vitro ubiquitination, poly-ubiquitin chains
with sizes above 3-Ub (over 25 kDa) were quantified using ImageJ and values were normalized to the
quantity of E3 ubiquitin ligase used in the reaction. The resulting normalized values were plotted and
the rate was calculated by dividing the normalized absorbance of poly-ubiquitin chains by the reaction
time. The normalized absorbance and calculated rates are relative and have an arbitrary unit.
3. Results
3.1. Deletion or Mutation of the B-box Domain Does Not Prevent TRIM32 E3 Ligase Catalytic Activity
The strictly conserved N-terminal structure of TRIM proteins suggests a potential function in
catalytic activity regulation of the single domains within the tripartite module. This module may have
evolved to serve as a scaffold to confer proper spacing and orientation to the catalytic RING domain
and the substrate interacting domain. In the case of TRIM32, the role of the tripartite motif domains
is still unclear and the available data on their contribution to E3 activity mainly rely on experiments
using short protein fragments [7,31]. In this study, we focused on characterizing the role of the B-box
type 2 domain of TRIM32 as a potential modulator of its activity. The B-box domain is a Zn-binding
domain, assuming a fold similar to the catalytic RING domain but with a still undefined role. We
generated a deletion mutant lacking the RING domain (∆RING) to investigate whether the B-box
could substitute for the RING to sustain catalytic activity (Figure 1). To further analyze the role of
the B-box, we generated a mutant lacking the whole B-box domain (∆B-box) and a mutant carrying
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mutations in two of the B-box cysteine residues necessary to coordinate the Zn2+ ions (C100A/C103A),
predicting that the resulting protein would have an unfolded B-box but would maintain the spacing
between the TRIM32’s RING and coiled-coil domains (Figure 1).Cells 2019, 8, x FOR PEER REVIEW 5 of 16 
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Figure 1. Schematic diagram showing the domain struct re of TRIM32 an t l tion/point mutants
used in this study.
We first assayed the activity of recombinant wild-type TRIM32 or mutants in the presence of the
UbE2D1 conjugating enzyme, previously shown to cooperate with TRIM32 to build poly-ubiquitin
chains [32], in the a sence of specific substrates. All proteins teste but the ∆RING were able to
build poly-ubiquitin chains in vitro in these experimental conditions and, strikingly, no difference
was observed between the activity of the ∆B-box, the C100A/C103A and wild-type TRIM32 proteins
(Figure 2). These results confirm that the cataly ic activity resides in the RING domain, as already
shown for other me bers of the TRIM family [33,34]. On the other hand, despite the structural
similarity, the B-box domain cannot substitute the RING in promoting the discharge of ubiquitin from
the loaded E2 as demonstrated by the lack of activity of the ∆RING mutant (Figure 2). Furthermore,
these data indicate that neither mutation nor the deletion of the B-box has dramatic effects on the
ability of TRIM32 to build poly-ubiquitin chains.
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Figure 2. TRIM32 carrying mut ns or deletion of the B-box shows activity similar to the
wild-type protein. Increasing doses of recombinant full-length TRIM32 (FL), ∆RING (∆R),
∆B-box (∆BB) or C100A/C103A mutants were used as E3 ligase in an in vitro reaction with the
UbE2D1 conjugating enzyme. Proteins were resolved by SDS-PAGE and poly-ubiquitin chains detected
with anti-ubiquitin antibody.
3.2. The B-box Domain Plays a Role in Modulating TRIM32 E3 Ligase Reaction Rate
The results of the previous section show that deletion or mutation of the TRIM32 B-box domain
has no effect on catalytic activity when the amount of poly-ubiquitin chains produced by the various
constructs is measured at the endpoint of the reaction. It is, however, possible that the B-box, either
through cooper tion with the RING or simply as spacer between the RING and the C-terminal
domains, may be i volved in modulating the rate at which TRIM32 builds the poly-ubiquitin
chains, as it was recently shown for the coiled-coil domain of the RING-type E3 ligase, TRAF6,
in the ubiquitination reaction with UbE2N/V2 [35]. We thus performed a time course experiment
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using UbE2N/V2, previously shown to work with TRIM32 [32], together with full-length TRIM32,
∆B-box and C100A/C103A and analyzed the progressive appearance of poly-ubiquitin chains by
ubiquitin immunoblot of SDS-PAGE-resolved reaction mixtures taken at different time points (Figure 3).
Confirming the previous results, no major difference was observed in the endpoint amounts of
poly-ubiquitin chains produced by the different constructs with this E2 enzyme too (Figure 3, Time
30 min). Interestingly however, the analysis of earlier time points revealed that the construct lacking
the B-box (∆B-box) presents a slightly enhanced ability to build poly-ubiquitin chains when compared
to the full-length protein. In particular, upon quantification of the poly-ubiquitin chains produced by
the different constructs, we observed that the TRIM32 reaction rate was not affected by point mutations
in the B-box, since the wild-type and C100A/C103A mutant showed comparable ability to build
poly-ubiquitin chains with small amounts of high molecular weight chains that appeared after 5 min
of reaction and progressively increased over time. However, when the B-box was deleted, we observed
an increased reaction rate and indeed, larger amounts of poly-ubiquitin chains were produced by
the ∆B-box construct at earlier time points compared to the full-length protein, either wild-type or
carrying point mutations in the B-box domain (Figure 3D). Altogether, these results suggest a role for
the B-box as a spacer able to modulate TRIM32 catalytic activity in vitro.
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Figure 3. Deletion f the TRIM32 B-box domain aff t t e rate of poly-ubiquitin chain formation.
Comparable amounts of full-length TRI 32 (A), C100A/C103A (B) or ∆B-box (C) mutants were
used in an in vitro ubiquitination reaction with the UbE2N/V2-conjugating enzymes. Samples were
taken at the indicated time points and proteins were resolved by SDS-PAGE. Poly-ubiquitin chains
were detected by anti-ubiquitin immunoblot (top panels) followed by stripping and reprobing of the
membrane with anti-TRIM32 antibody (bottom panels). (D) Poly-ubiquitin chains were quantified,
normalized to the amount of E3 used in the assay and plotted (solid lines). The observed reaction rate
was calculated and plotted (dashed lines). Equations showing the calculated reaction rate for each
construct are shown. Average and standard error of five independent experiments are represented.
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3.3. TRIM32 E2 Specificity Is Not Determined by the B-box
In the RING-mediated ubiquitination process, the E2-conjugating enzyme can determine the
topology of poly-ubiquitin chains on the modified substrate. However, since the latter is recognized
specifically by the E3, it follows that different E2–E3 combinations will differentially affect the fate
of substrates (reviewed in [36]). Previous data from our group indicate that the majority of TRIM
proteins interact and work with E2s with defined specificity [32]. The results above suggest a role for
the B-box in modulating TRIM32 catalytic activity, potentially by regulating the interaction between
the catalytic RING domain and the ubiquitin-loaded E2. In this scenario, we next considered whether
the B-box might thus modulate the E2 specificity, ultimately controlling the topology of the chains
built by TRIM32. To this end, we tested the ability of recombinant full-length TRIM32 or carrying
a deletion of either the RING or the B-box domain to build poly-ubiquitin chains in cooperation
with 29 different E2-conjugating enzymes in vitro. Consistent with previous results and extending
these data, TRIM32 was able to build poly-ubiquitin chains with E2 enzymes of the D family
(UbE2D1-D4), UbE2N and UbE2N in combination with UbE2V2 (Figure 4, anti-ubiquitin immunoblot).
We observed the auto-ubiquitination of TRIM32 in the presence of UbE2D-conjugating enzymes in
the form of a typical ladder (Figure 4, top panels, anti-TRIM32 immunoblot). Employing UbE2N
and UbE2N/V2, we observed the formation of high molecular weight species (Figure 4, bottom
panels, ubiquitin immunoblots), which likely represent free ubiquitin chains [37]. Interestingly, the
anti-TRIM32 immunoblot also showed that TRIM32 promotes the self-addition of a single ubiquitin
moiety in cooperation with UbE2E1 and E3, and with the mono-ubiquitinating UbE2W enzyme,
consistent with the assessed role for these enzymes in ubiquitination [38,39] (Figure 4, bottom panels,
anti-TRIM32 immunoblot). The other assayed UbE2s did not sustain the formation of poly-ubiquitin
chains, thus indicating a marked UbE2 specificity (Figure S1).
As observed in previous in vitro experiments, the deletion of the RING domain abolishes
TRIM32 activity in all cases, confirming that the catalytic activity resides in this domain and that
the B-box cannot mediate ubiquitination with any of the E2 tested. Of note, with all the UbE2s
above, the activity of full-length TRIM32 is comparable with the ∆B-box protein when used as E3 in
the reaction. No major difference was observed not only in the auto-poly-ubiquitination reactions
(UbE2D1-4), but also when mono-ubiquitination (UbE2E1, E3, W) or formation of free ubiquitin chains
(UbE2N, N/V2) was catalyzed (Figure 4). These data indicate that the deletion of the B-box domain
does not affect TRIM32 E2 specificity or ubiquitinating ability when examined at the endpoint of the
reaction. The same holds true for the UbE2s not supporting activity with the full-length TRIM32,
which do not show variations when the ∆B-box mutant is employed (Figure S1). Altogether, these
results indicate that the deletion of the B-box domain does not affect TRIM32 E2 specificity in vitro.
3.4. The RING Domain Is Involved in Higher-Order Self-Association of TRIM32
Structural and biochemical studies have demonstrated that the coiled-coil domain in TRIM
proteins is necessary for dimerization, while other domains, such as the B-box domain in the case
of TRIM5α, are necessary to mediate the higher-order self-association of TRIM proteins [17,19,20].
In TRIM32, the isolated RING, as well as the RING-B-box fragment, exists as a dimer; however,
the construct containing the RING, B-box and coiled-coil domains is tetrameric in solution [7]. To
investigate the potential role of RING and B-box in regulating the self-association of TRIM32, we
next examined the oligomerization status of TRIM32 full-length or carrying deletions of one of these
domains by native PAGE electrophoresis. The results in Figure 5 show the presence of high molecular
weight species formed by the oligomerization of the full-length TRIM32 protein (Figure 5). Strikingly,
the formation of high molecular weight species is greatly reduced when the construct lacking the RING
domain is examined, while the deletion of the B-box does not affect TRIM32 oligomerization. Indeed,
SDS-resistant high molecular weight complexes were also observed in the TRIM32 immunoblots
presented in Figure 4, and these were consistently not formed in the presence of the ∆RING mutant.
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Taken together, these observations indicate that the RING domain, rather than the B-box domain, is
critical for the stabilization of higher-order oligomers in the case of TRIM32.Cells 2019, 8, x FOR PEER REVIEW 8 of 16 
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3.5. The RING and B-box Domains Contribute to Specify TRIM32 Subcellular Localization
So far, the experiments have focused on in vitro auto-ubiquitination activity. Thus, to start
characterizing the role of different TRIM32 domains belonging to the tripartite module in an in vivo
context, we next analyzed the subcellular localization of TRIM32 constructs by expressing the
GFP-tagged full-length, RING or B-box domain deletion mutants or the B-box point mutant in
the murine myoblast cell line, C2C12 (Figure 6). Like many TRIM family members, TRIM32 was
shown to form characteristic cytoplasmic bodies that are evident when expressing the full-length
protein [32,40,41]. The speckles are small and distributed throughout the cytoplasm. Interestingly,
the localization of the protein lacking the RING domain appears to be more perinuclear and the
cytoplasmic bodies formed are larger as compared to the full-length protein. The proteins lacking the
B-box or carrying mutations in the B-box Zn-coordinating residues, on the other hand, appear to have
a more diffuse cytoplasmic localization with only some cells showing the typical punctate localization
(Figure 6).Cells 2019, 8, x FOR PEER REVIEW 10 of 16 
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We next ex mined the interplay between the different TRIM32 domains in specifying its
subcellular localization by co-expressing constructs lacking the B-box with the full-length or ∆RING
mutant. In keeping with previous observations, the results in Figure 7 show that constructs lacking
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the B-box assume a more diffuse localization within the cell, with some small cytoplasmic bodies
dispersed in the cytoplasm (Figure 7, middle panels). Interestingly, the co-localization of full-length
TRIM32 with the ∆B-box mutant is observed within cytoplasmic bodies; however, part of the ∆B-box
protein remains diffuse in the cytoplasm even in the presence of wild-type TRIM32. Likewise, in
presence of the ∆RING mutant, the protein lacking the B-box domain remains diffuse in the cytoplasm.
Strikingly however, the construct lacking the RING domain is able to recruit the ∆B-box mutant in the
large perinuclear structures typically formed in absence of the RING domain. Taken together, these
results confirm that both the RING and B-box domains are critical in specifying TRIM32 sub-cellular
localization. However, the ability of mutants lacking the N-terminal domains to localize in the same
sub-cellular structures suggests that other domains, including the coiled-coil, are likely involved in
mediating self-association, while the N-terminal domains may be necessary to specify sub-cellular
localization by directing localization towards yet-to-be-identified specific sub-cellular structures. This
in turn may represent an important mechanism to regulate interactions with specifically localized
pools of substrates and relevant E2-conjugating enzymes, ultimately controlling the enzymatic activity.
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4. Discussion
In this work, we investigated the role of the Zn-binding domains of the tripartite motif of TRIM32.
Biochemical studies originally identified a role for the RING domain in TRIM proteins in promoting
the direct transfer of ubiquitin from a loaded E2 to the substrate and this feature is also conserved in
other RING-type E3 ligases not belonging to the TRIM family, such as Ring Finger protein 4 (RNF4) or
Mouse double minute 2 (Mdm2) [42,43] and reviewed in [2]. However, a hallmark of TRIM proteins
is the presence, C-terminal to the RING, of conserved B-box motifs that, in animals, are exclusive to
this protein family and are predicted to assume a fold similar to the RING itself through Zn atom
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coordination [12–14]. It has been hypothesized, therefore, that the B-box domains could act as the
RING domains to promote the building of poly-ubiquitin chains. Indeed, a very weak catalytic activity
was observed in vitro for the RING-less TRIM member, TRIM16, and interestingly, the activity was
shown to depend on the presence of the B-box domains [44]. Our in vitro analysis revealed, however,
that the B-box in TRIM32 is unable to substitute for the RING to promote the building of ubiquitin
chains, as already observed for other members of the family [33,45,46]. Of note, TRIM16 possesses
a B-box tandem repeat formed by a B-box type 1 and a B-box type 2 domain, while TRIM32 holds
a single type 2 B-box domain. Of the two domains, the type 1 B-box was shown to present a higher
level of similarity to the RING domain and, furthermore, the tandem B-box repeats of another TRIM
family member, MID1, were shown to form an intramolecular complex resembling a RING dimer [47].
It is therefore tempting to speculate that the intrinsic characteristics of the type 1 B-box together with
the possibility to dimerize with the type 2 B-box might explain the weak activity observed for the
RING-less TRIM16 and that, in other TRIM proteins possessing a single type 2 B-box, such as TRIM32,
the ubiquitination relies exclusively on the presence of the RING domain.
To further characterize the potential role of the B-box, we compared the reaction rate of full-length
TRIM32 with the ∆B-box and C100A/C103A constructs. One previous report indicated the possibility
that the C-terminal NHL domain in TRIM32 is involved in binding of UbE2N [48]. While, as
mentioned previously, the interaction of the loaded E2 with the RING is necessary for the ubiquitination
reaction, binding of the E2 to domains other than the RING may be a mechanism to increase the local
concentration of ubiquitin-loaded E2s and may thus affect the processivity of the reaction. Indeed, such
a mechanism was shown to be employed by the E3 ligase TRAF6 that, upon oligomerization, binds the
ubiquitin-loaded E2s with its coiled-coil domain, thus increasing their availability for the RING domain
to achieve the rapid building of long poly-ubiquitin chains [35]. In this scenario, we hypothesized that
the ∆B-box construct, having a reduced distance between the NHL and the RING, may present an
increased reaction rate compared to the C100A/C103A mutant, which retains the full B-box, albeit
mutated. Indeed, a comparison of the time-dependent production of poly-ubiquitin chains generated
by the full-length, ∆B-box and C100A/C103A constructs revealed that the protein lacking the B-box
is slightly more efficient in building poly-ubiquitin chains when compared to the full-length and the
B-box point mutant, in particular in the first stages of the reaction. On the other hand, point mutation
of the B-box resulted in an activity and reaction rate comparable to the wild-type protein. Therefore,
our results indicate that the B-box may also act as a spacer to regulate TRIM32 processivity. However,
the exact mechanism and the potential involvement of domains other than the RING in interaction
with the ubiquitin-loaded E2 need further study.
We also assessed the potential involvement of the B-box in determining E2 specificity. In our
analysis, the protein carrying a deletion of the B-box showed the same E2 specificity of the full-length
one, indicating that the B-box is likely not involved in interaction with the E2. Indeed, previous studies
have shown that the RING domain of TRIM32 is strictly necessary for interaction with UbE2N, while a
TRIM32 mutant lacking the B-box domain maintains the interaction in a Yeast Two-Hybrid setting,
further indicating that the B-box is not necessary for association with the E2 [32]. The inability of
TRIM32 B-box to interact with the E2 also potentially explains its lack of activity, since interaction
with the ubiquitin-loaded E2 was shown to be at the basis of the conformational change necessary to
promote the discharge of ubiquitin from the E2 active site (reviewed in [49]). However, we cannot
exclude that the B-box may bind the nascent ubiquitin chain. In this scenario, it would be intriguing to
investigate whether the B-box may play a role, together with the E2, in determining the topology of the
ubiquitin chain. Furthermore, experiments presented in this study did not investigate the possibility
that the B-box may be involved in substrate recognition, as is the case for the B-boxes in MID1 [50],
thus the role of TRIM32 B-box in the context of substrates modifications awaits further studies.
The TRIM5α B-box domain was shown to be necessary to promote the formation of the lattice
required for HIV capsid recognition and for the dimerization of the RING domains necessary for
activity [15,19]. Likewise, Small-angle X-Ray Scattering (SAXS) analysis revealed that TRIM32 forms
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tetramers in solution deriving from the juxtaposition of two dimers formed through coiled-coil
interactions [7]. To our surprise, while the B-box is dispensable for the formation of TRIM32 oligomers
in vitro, these are greatly reduced in absence of the RING domain, which must thus play a critical role
in the stabilization of oligomers. Indeed, the RING domain of TRIM5α was also shown to contribute
significantly to self-association [51].
Within a cellular context, however, analysis of the subcellular localization revealed that both
the RING and B-box are involved in determining TRIM32 localization, as already observed for other
members of the TRIM family [3]. The typical cytoplasmic bodies formed by the oligomerization
of wild-type TRIM32 appear in fact to be altered when the RING or B-box domains are absent or
mutated, with the lack of the RING leading to the formation of larger aggregates less dispersed
in the cytoplasm while the lack of B-box, on the other hand, results in the reduced formation of
aggregates/cytoplasmic bodies, indicating that both the RING and B-box domains play a role in
determining TRIM32 sub-cellular localization in vivo. Of note, both a complete deletion of the
B-box and a 2-residue-substitution likely leading to an improperly folded domain, despite a different
behavior shown in in vitro ubiquitination, have the same effect on TRIM32 localization. This might
suggest different roles of this conserved domain in biochemical activity and in cellular distribution.
Interestingly, a domain similar to the B-box was identified in the deubiquitinase enzyme CYLD,
where it was also shown to be necessary to determine its cytoplasmic localization probably through
interactions with cytosolic proteins [52]. Likewise, upon co-expression, we were able to observe the
co-localization of mutants lacking either the RING or B-box domain, indicating that these deletion
mutants retain the ability to self-associate. However, altered localization of the ∆RING and ∆B-box
mutants suggests the possibility that these domains may specify TRIM32 subcellular localization
by mediating interactions with specific subcellular structures. Furthermore, since cytoplasmic body
formation is a dynamic process which regulates the pool of soluble and active TRIM32 present in
cells and thus the interaction with partner proteins, the RING and B-box domains therefore assume
a critical role in the regulation of this process, ultimately controlling TRIM32 activity [53]. In future
studies, it will be interesting to assess the composition of these cytoplasmic compartments in terms of
ubiquitination machinery components and specific disease-related substrates.
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